News

First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia

GlaxoSmithKline's Ebola candidate will be the first of several experimental vaccines to undergo large-scale clinical trials. On Friday, the company shipped an initial batch of 300 vials of the vaccine, ChAd3, to Liberia, one of the main countries affected by Ebola.

Serum Institute of India poses challenge to Merck HPV vaccine

The Serum Institute of India, the world's fifth largest vaccinemaker by volume, is eyeing newer vaccines, including one for the human papillomavirus expected to be launched by late 2018 and sell at a third of the price of Merck & Co.'s blockbuster Gardasil, Bloomberg reported.

Pfizer wins recommendation for Prevenar expansion in Europe

The European Medicines Agency accepted Pfizer's application to expand its label for blockbuster vaccine Prevenar 13 back in August, and so far, an advisory committee likes what it sees.

Disneyland measles outbreak adds fuel to heated anti-vaccination debate

The measles outbreak that began at Disneyland is spreading across California and beyond, and it's reigniting a heated debate over the anti-vaccination movement.

After rocky flu season, vaccinemakers may want to follow Novartis' lead

Heading into this year's flu season, vaccinemakers were hoping to follow up the top-line success they scored last year with quadrivalent rollouts. But with this year's vaccines registering a paltry 23% effectiveness rate this season thanks to a mutated strain, it might be time to make some changes.

Takeda eyeing vaccinemakers as entry point to India

SINGAPORE--Takeda Pharmaceutical has identified a handful of Indian vaccinemakers as targets for M&A or other deal structures as it gets ready to take a plunge into a market that saw rival Daiichi Sankyo find nothing but trouble, according to sources that have spoken to executives at the Japanese company.

Study: GSK's malaria vaccine may not be effective when used with bed nets

In July last year, GlaxoSmithKline submitted its malaria vaccine, RTS,S, for regulatory review by the European Medicines Agency. Because there are no existing malaria vaccines, Glaxo says that a vaccine to be used "alongside other measures such as bed nets and anti-malarial medicines" would be an advance in malaria control. However, a new study published Monday might have GSK rethinking the bed nets.

J&J forms consortia to accelerate Ebola vaccine development, gets €100M boost from IMI

Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.

MSF urges GSK, Pfizer to slash pneumococcal vaccine prices

The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.

PaxVax ready to strike M&A deals that prove its sales model, CEO says

PaxVax entered the M&A arena last summer, nabbing typhoid vaccine Vivotif from Johnson & Johnson subsidiary Crucell. And it's not stopping there, CEO Ken Kelley says.

China approves world's first inactivated Sabin polio vaccine

China's FDA has green-lighted the world's first Sabin strain inactivated polio vaccine--and a locally produced one, at that.

Pfizer developing cholesterol-fighting vaccine as part of PCSK9 'franchise'

PCSK9 drugs are the next big market waiting to happen, and with rivals Sanofi/Regeneron and Amgen ahead in the development race, Pfizer wants to make sure it can lock down a solid share of the market. So beyond in-development anti-cholesterol antibody bococizumab, it's working on a wider PCSK9 "franchise," R&D chief Mikael Dolsten said Tuesday at the JP Morgan Healthcare Conference--and that includes a vaccine.

J&J partners with AC Immune on anti-tau Alzheimer's vaccine

Scientists don't fully understand what causes Alzheimer's disease yet and success on the vaccines front has been limited, but Johnson & Johnson and Swiss biopharma AC Immune will nonetheless be partnering to develop a therapeutic vaccine for the disease.

WHO approves MenAfriVac for routine infant immunization in sub-Saharan Africa

The affordable meningitis A vaccine, MenAfriVac, has been given to millions of people in Africa's so-called "meningitis belt," and is about to be administered to even more. The World Health Organization approved the shot, previously approved for people aged one to 29, for use in the routine immunization of infants less than one year old in sub-Saharan Africa.

Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa

GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.

Zydus Cadila ups vaccines game with programs for Ebola, Congo fever

The latest drugmaker diving into the Ebola vaccine race? India's Zydus Cadila.

No link between Merck's Gardasil and MS risk, study shows

Merck and partner Sanofi can breathe easy: According to a new study, their blockbuster Gardasil isn't linked to an increased risk of multiple sclerosis.

Valneva picks up J&J's cholera vaccine--and some forthcoming competition

Johnson & Johnson's Crucell is officially out of the cholera space, and France's Valneva is in. And that means it's Valneva that's about to inherit some hefty competition that's coming up through its rivals' pipelines.

Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late?

Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J's candidate come too late to catch up with its rivals and help combat the current epidemic?

Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose

The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.